Lv2
150 积分 2023-05-23 加入
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
25天前
已完结
Next-generation T-cell engagers for solid tumor immunotherapy
1个月前
已关闭
Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger
2个月前
已完结
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
4个月前
已完结
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
4个月前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
6个月前
已完结
The present and future of bispecific antibodies for cancer therapy
7个月前
已完结
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an antiPD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
7个月前
已完结
PD1 × VEGF blocking bispecifics for cancer draw big backing
7个月前
已完结
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
8个月前
已完结
皖公网安备34019202002308
